SEC Form 4 · accession 0001179110-15-009321
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William K Heiden
Officer — CEO · Director
Period of report
Jun 5, 2015
Accepted (ET)
Jun 8, 2015 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 5, 2015 | S | 6,875 | $68.14 | D | 208,721 | D | |
| Common Stock | Jun 5, 2015 | M | 60,000 | $12.99 | A | 268,721 | D | |
| Common StockF2 | Jun 5, 2015 | S | 6,642 | $68.90 | D | 262,079 | D | |
| Common StockF3 | Jun 5, 2015 | S | 36,550 | $69.77 | D | 225,529 | D | |
| Common StockF4 | Jun 5, 2015 | S | 4,680 | $70.69 | D | 220,849 | D | |
| Common StockF5 | Jun 5, 2015 | S | 12,128 | $71.52 | D | 208,721 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $12.99 | Jun 5, 2015 | M | 60,000 | A | — | May 14, 2022 | Common Stock | 60,000 | 230,000 | D |
Explanation of responses
- F1The reported transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2015.
- F2The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual prices per share range from $68.14 to $69.13, inclusive. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
- F3The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual prices per share range from $69.15 to $70.00, inclusive. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
- F4The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual prices per share range from $70.18 to $71.15, inclusive. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
- F5The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual prices per share range from $71.20 to $71.25, inclusive. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc., or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
- F6This option vests and becomes exercisable in four equal annual installments beginning May 14, 2013.